Clinical Trial Update: A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of Trastuzumab Rezetecan for unresectable locally recurrent or metastatic breast cancer is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab Rezetecan

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING